Back to News
Market Impact: 0.2
Milestone Moves Etripamil AFib-RVR Program Forward With First European Patient; Stock Up
Source: Nasdaq
Healthcare & Biotech
Milestone Pharmaceuticals announced enrollment of the first European patient in its Phase 3 ReVeRA-301 trial of etripamil nasal spray for atrial fibrillation with rapid ventricular rate (AFib-RVR). The update marks progress in the clinical trial; the article excerpt provides no efficacy results or additional enrollment details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
MIST0.45
More News
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Humana Stock Jumps on Raised Medicare Advantage Ratings
- Premarket movers: Humana rallies; SpaceX deal sends telco stocks down
- Baird upgrades Humana stock rating on margin recovery outlook
- HIMS jumps 7% on peptide tailwind — but Citi sees 17% downside from here